GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding tripeptide composed of the amino acids glycine, histidine, and lysine complexed with copper (Cu²⁺). It was first isolated from human plasma in the 1970s and has since been identified in saliva and urine. GHK levels naturally decline with age.
GHK-Cu has been extensively studied for its potential role in skin remodeling, wound healing, collagen synthesis, tissue regeneration, angiogenesis, antioxidant activity, and anti-inflammatory effects. Because of these biologic properties, GHK-Cu has become a common ingredient in topical cosmetic formulations and has also been investigated as an injectable peptide for regenerative medicine.
Although laboratory and early clinical studies are encouraging, GHK-Cu is not FDA-approved as an injectable drug for any medical indication in the United States. The FDA has identified safety concerns regarding compounded injectable GHK-Cu because of limited human safety data and the potential for peptide impurities and immunogenicity.
GHK-Cu functions as both a copper transport peptide and a regulator of numerous cellular repair pathways.
Research suggests GHK-Cu may:
Unlike many growth factor therapies, GHK-Cu appears to regulate multiple repair pathways simultaneously rather than acting through a single receptor. Much of this mechanistic evidence comes from laboratory and preclinical studies.
Published research suggests GHK-Cu may provide several biologic effects.
Potential benefits may include:
While several placebo-controlled cosmetic studies have demonstrated improvements in aging skin, most proposed systemic or injectable uses remain investigational and are supported primarily by laboratory and animal data rather than large randomized clinical trials.
Topical GHK-Cu has generally demonstrated a favorable safety profile in cosmetic studies.
Potential adverse effects include:
The FDA has specifically noted that compounded injectable GHK-Cu may pose safety concerns because of peptide aggregation, impurities, and limited human safety data.
GHK-Cu should generally be avoided or used only with caution in individuals with:
Patients with chronic illnesses or complex medical conditions should consult a qualified healthcare provider before considering GHK-Cu therapy.
Injectable GHK-Cu
GHK-Cu is not FDA-approved for any injectable medical indication in the United States.
The FDA has identified safety concerns regarding compounded injectable GHK-Cu because available human safety information is limited and compounded preparations may present risks related to immunogenicity and peptide impurities.
Topical Cosmetic Products
Copper peptides, including GHK-Cu, are commonly used in cosmetic skincare products marketed to improve the appearance of aging skin. These cosmetic products are regulated differently than prescription drugs and should not be interpreted as FDA approval for medical treatment.
Human Studies
Human clinical research has focused primarily on skin aging and wound healing.
Published studies have demonstrated that topical GHK-Cu may:
Small placebo-controlled clinical studies have reported improvements in skin quality among middle-aged women following topical GHK-Cu treatment. However, evidence supporting injectable or systemic use remains limited, and large randomized clinical trials are lacking.
Animal & Preclinical Studies
Animal and laboratory studies have demonstrated that GHK-Cu may:
These findings provide biologic plausibility but do not establish clinical efficacy for common off-label injectable uses in humans.
Human Studies
Animal & Preclinical Studies
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, or outdated information.
GHK-Cu is not FDA-approved as an injectable drug for any medical indication in the United States. While topical copper peptide products are widely used in cosmetic skincare, injectable GHK-Cu remains investigational. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# MOTS-c